Developer docs
API playgroundTry for free, no card

Search company profiles

Neuron23

Full company profile

uuid0000egi

Namestring
Neuron23
Legal namestring
Neuron23 Inc.
Websiteurl
neuron23.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Neuron23 is a clinical-stage biotechnology company founded in late 2018 and headquartered in South San Francisco, California, that develops precision medicines for genetically defined neurodegenerative and immunological diseases. The pipeline is anchored by NEU-411, an oral, brain-penetrant, selective LRRK2 kinase inhibitor currently in the global Phase 2 NEULARK trial for early Parkinson's disease, with topline data anticipated in 2027. A second LRRK2 candidate, NEU-723, completed first-in-human Phase 1 dosing, while the company separately advances TYK2 inhibitors NEU-111 (Phase 1, oral allosteric inhibitor for immune-mediated inflammatory disorders) and NEU-627 (preclinical, brain-penetrant for multiple sclerosis).

The company's underlying technology is an integrated precision-medicine stack: a proprietary machine-learning patient selection model that identifies SNP signatures predictive of LRRK2 pathway overactivity in up to 30% of idiopathic PD patients; a first-of-its-kind next-generation sequencing companion diagnostic co-developed with QIAGEN and deployed exclusively at Quest Diagnostics; and a smartphone-based digital biomarker from Roche Information Solutions that serves as the primary endpoint in NEULARK. Neuron23 frames this as a disease-modifying approach that targets underlying drivers of PD progression rather than symptoms.

Neuron23 generates no product revenue today and operates a traditional biotech commercialization model. Capital is raised through successive venture rounds — over $310 million cumulatively across Series B, C, and D plus a $2.5 million Michael J. Fox Foundation grant — and the company has signaled that any approved therapy would likely be distributed through specialty pharmacies, healthcare providers, or partnership/licensing arrangements with larger pharmaceutical companies. Revenue mechanics through 2027 will be milestone- or royalty-based rather than product-based.

Short descriptiontext

Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined Parkinson's disease and immune-mediated disorders, anchored by the Phase 2 LRRK2 inhibitor NEU-411 and a proprietary machine-learning patient stratification platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision medicine therapeutics, LRRK2 inhibitor development, Parkinson's disease drugs, companion diagnostic development, clinical-stage biotechnology
Industry2 codes
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAANAH
Patient Stratification, Risk Prediction & Prognostic Modeling
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical/Drug Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biotechnology company, Neuron23's primary revenue model will be through the development and commercialization of novel therapeutics. The company is developing precision medicines for genetically defined neurological and immunological diseases, with lead programs NEU-411 (LRRK2 inhibitor for Parkinson's disease) and NEU-111 (TYK2 inhibitor for immune disorders). Successful commercialization would occur through direct sales, licensing agreements, or partnership with larger pharmaceutical companies.

neuron23.com
2Companion Diagnostic Partnerships
TypeLicensing Royalties
Description

Revenue may be generated through partnerships with diagnostic companies (QIAGEN, Quest Diagnostics) for companion diagnostic development and commercialization. These partnerships support clinical development and may include future royalty or revenue-sharing arrangements.

neuron23.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined neurological and immunological diseases. Its pipeline comprises brain-penetrant LRRK2 inhibitors (lead asset NEU-411 in Phase 2 NEULARK for early Parkinson's disease, plus NEU-723) and TYK2 inhibitors (NEU-111 in Phase 1 for immune-mediated inflammatory disorders, plus preclinical NEU-627 for neuroinflammation). The drug programs are paired with a proprietary machine learning patient selection model and a first-in-class NGS companion diagnostic (developed with QIAGEN) that identifies patients with LRRK2-driven Parkinson's disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • LRRK2 pathway engagement demonstrated with dramatic reductions in pS935-LRRK2 in blood and cerebrospinal fluid
+3 more records
Product overview1 text field

Neuron23 is a clinical-stage biotechnology company developing a portfolio of precision medicines for genetically defined neurological and immunological diseases. The company's pipeline includes three clinical-stage programs: NEU-411 (Phase 2, LRRK2 inhibitor for Parkinson's disease), NEU-723 (Phase 1 completed, LRRK2 inhibitor for PD), and NEU-111 (Phase 1, TYK2 inhibitor for immune-mediated disorders). The pipeline is supported by a precision medicine platform that integrates machine learning-based patient selection algorithms, companion diagnostics developed with QIAGEN for genetic testing, and digital biomarker technology from Roche for disease monitoring. The company is also advancing NEU-627, a brain-penetrant TYK2 inhibitor for multiple sclerosis.

Product and service5 records
1NEU-411
CategoryPrecision Medicine Therapeutics
Description

A brain-penetrant, potent and selective oral inhibitor of LRRK2 kinase currently being evaluated in the global Phase 2 NEULARK clinical trial for early Parkinson's disease. Targets LRRK2-driven PD affecting up to 30% of people with idiopathic Parkinson's disease, offering a disease-modifying approach versus existing symptomatic-only treatments.

2NEU-723
CategoryPrecision Medicine Therapeutics
Description

A highly potent and selective brain-penetrant LRRK2 inhibitor that completed first-in-human Phase 1 clinical trial in healthy volunteers. Demonstrated strong disease-modifying potential with a higher therapeutic index than other LRRK2 candidates in development.

3NEU-111
CategoryPrecision Medicine Therapeutics
Description

A potent and highly selective oral allosteric inhibitor of TYK2 (tyrosine kinase 2) in Phase 1 clinical trials for immune-mediated inflammatory disorders. Reduces signaling through cytokine receptors including IL-12, IL-23 and interferon-alpha with potential applications in inflammatory bowel diseases, lupus, rheumatoid arthritis, and Type 1 diabetes.

4NEU-627
CategoryPrecision Medicine Therapeutics
Description

A brain-penetrant TYK2 inhibitor in preclinical development for multiple sclerosis and neuroinflammatory diseases, representing Neuron23's expansion into neuroinflammatory conditions.

5Precision Medicine Platform
CategoryDrug Discovery Platform
Description

An integrated platform combining machine learning algorithms, human genetics, and biomarker discovery to identify genetic signatures predictive of therapeutic response. Utilizes companion diagnostics (developed with QIAGEN) and digital biomarkers (with Roche) to enable patient stratification and selection for targeted therapies.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-26
Description

PD Trial Navigator program partnership. Foundation identified over 2,000 genetically eligible potential participants for NEULARK clinical trial by leveraging PD GENEration database of over 30,000 genetically tested Parkinson's patients combined with Neuron23's precision medicine tools.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-03-25
Description

Research collaboration for nonclinical studies on TYK2 inhibitors demonstrating impact in EAE model of multiple sclerosis and neuroinflammation. Studies conducted in collaboration with the Tisch Institute contributed to PNAS publication.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-11-19
Description

Collaboration to incorporate digital biomarker developed by Roche as primary endpoint in Phase 2 NEULARK clinical trial. Roche provides device hardware, software, site support, and digital biomarker development expertise. Participants use smartphone equipped with proprietary software to measure PD symptoms.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-19
Description

Partnership to streamline patient referrals for NEULARK clinical trial. Sano offers saliva test kits that can identify people with LRRK2-driven PD and provides genetic counseling and engagement tools. Identified individuals referred to nearest NEULARK site.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-09-14
Description

Master Collaboration Agreement to develop companion diagnostic for LRRK2 inhibitor for Parkinson's disease. QIAGEN developing clinical trial assay using NGS workflow to detect biomarkers predictive of patient responsiveness. Quest Diagnostics deploying assay at laboratory in San Juan Capistrano, CA under exclusive agreement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Denali Therapeutics is the most directly comparable peer, developing a brain-penetrant LRRK2 inhibitor (BIIB122/DNL151) for Parkinson's disease in partnership with Biogen. Both companies target LRRK2-driven PD using a similar precision medicine framing and represent the leading edge of LRRK2 clinical development globally.

TypeDirect peer
Description

Prothena is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases including Parkinson's and Alzheimer's, sharing Neuron23's CNS drug development focus and clinical-stage biotech operating model.

TypeBroad incumbent
Description

Intra-Cellular Therapies develops CNS therapeutics (CAPLYTA for schizophrenia and bipolar depression) with broader neuroscience focus, established regulatory and commercial infrastructure that parallels Neuron23's CNS disease focus at greater scale.

TypeBroad incumbent
Description

Acadia Pharmaceuticals is an established biopharmaceutical company commercializing CNS therapies including treatments for Parkinson's disease psychosis (NUPLAZID), representing a commercially validated competitor/incumbent in the PD therapeutic market.

TypeOthers
Description

Biogen is a large biopharmaceutical company with established CNS franchise (TYSABRI, SPINRAZA, ADUHELM) that partners with Denali on the leading LRRK2 inhibitor; represents the type of potential strategic acquirer/partner for Neuron23's NEU-411 program.

TypeDirect peer
Description

Annexon is a clinical-stage biopharmaceutical company developing complement-mediated therapies for neurodegenerative diseases, sharing Neuron23's focus on targeted therapeutics for neurological conditions and clinical-stage development posture.

TypeDirect peer
Description

Voyager Therapeutics is a clinical-stage gene therapy company with Parkinson's disease programs (including tau-targeted and GBA1 approaches), mirroring Neuron23's targeted therapeutic strategy for genetically defined CNS disease subpopulations.

TypeDirect peer
Description

Sage Therapeutics developed CNS-targeting therapeutics (Zulresso, Zurzuvae) with a similar focus on neurological and neuropsychiatric indications, mirroring Neuron23's CNS drug development profile; acquired by Biogen in 2024.

TypeDirect peer
Description

Prevail Therapeutics was a clinical-stage gene therapy company developing AAV-based therapies for neurodegenerative diseases including Parkinson's disease with GBA1 mutations, acquired by Eli Lilly in 2021 for ~$880M. It shares Neuron23's precision medicine approach to genetically defined PD subpopulations.

TypeDirect peer
Description

Cerevel Therapeutics is a clinical-stage neuroscience company developing therapies for CNS disorders including Parkinson's disease, sharing Neuron23's CNS therapeutic focus, clinical-stage operating model, and similar investor sponsorship structure (including with Pfizer legacy program assets).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neuron23

Biopharmaceutical Therapeuticsneuron23.com

Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined Parkinson's disease and immune-mediated disorders, anchored by the Phase 2 LRRK2 inhibitor NEU-411 and a proprietary machine-learning patient stratification platform.

What Neuron23 does

Neuron23 is a clinical-stage biotechnology company founded in late 2018 and headquartered in South San Francisco, California, that develops precision medicines for genetically defined neurodegenerative and immunological diseases. The pipeline is anchored by NEU-411, an oral, brain-penetrant, selective LRRK2 kinase inhibitor currently in the global Phase 2 NEULARK trial for early Parkinson's disease, with topline data anticipated in 2027. A second LRRK2 candidate, NEU-723, completed first-in-human Phase 1 dosing, while the company separately advances TYK2 inhibitors NEU-111 (Phase 1, oral allosteric inhibitor for immune-mediated inflammatory disorders) and NEU-627 (preclinical, brain-penetrant for multiple sclerosis).

The company's underlying technology is an integrated precision-medicine stack: a proprietary machine-learning patient selection model that identifies SNP signatures predictive of LRRK2 pathway overactivity in up to 30% of idiopathic PD patients; a first-of-its-kind next-generation sequencing companion diagnostic co-developed with QIAGEN and deployed exclusively at Quest Diagnostics; and a smartphone-based digital biomarker from Roche Information Solutions that serves as the primary endpoint in NEULARK. Neuron23 frames this as a disease-modifying approach that targets underlying drivers of PD progression rather than symptoms.

Neuron23 generates no product revenue today and operates a traditional biotech commercialization model. Capital is raised through successive venture rounds — over $310 million cumulatively across Series B, C, and D plus a $2.5 million Michael J. Fox Foundation grant — and the company has signaled that any approved therapy would likely be distributed through specialty pharmacies, healthcare providers, or partnership/licensing arrangements with larger pharmaceutical companies. Revenue mechanics through 2027 will be milestone- or royalty-based rather than product-based.

Neuron23 firmographics

Firmographics
Name
Neuron23
Legal name
Neuron23 Inc.
Website
https://neuron23.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined Parkinson's disease and immune-mediated disorders, anchored by the Phase 2 LRRK2 inhibitor NEU-411 and a proprietary machine-learning patient stratification platform.
Ownership category
akta.pro rank

Neuron23 industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAANAH
Patient Stratification, Risk Prediction & Prognostic Modeling

Keywords

  • Precision medicine therapeutics
  • LRRK2 inhibitor development
  • Parkinson's disease drugs
  • Companion diagnostic development
  • Clinical-stage biotechnology

Where Neuron23 is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Neuron23 business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical/Drug Development and Commercialization: As a clinical-stage biotechnology company, Neuron23's primary revenue model will be through the development and commercialization of novel therapeutics. The company is developing precision medicines for genetically defined neurological and immunological diseases, with lead programs NEU-411 (LRRK2 inhibitor for Parkinson's disease) and NEU-111 (TYK2 inhibitor for immune disorders). Successful commercialization would occur through direct sales, licensing agreements, or partnership with larger pharmaceutical companies.
  2. Companion Diagnostic Partnerships: Revenue may be generated through partnerships with diagnostic companies (QIAGEN, Quest Diagnostics) for companion diagnostic development and commercialization. These partnerships support clinical development and may include future royalty or revenue-sharing arrangements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Neuron23 product offering

Product offering

Core offering

Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined neurological and immunological diseases. Its pipeline comprises brain-penetrant LRRK2 inhibitors (lead asset NEU-411 in Phase 2 NEULARK for early Parkinson's disease, plus NEU-723) and TYK2 inhibitors (NEU-111 in Phase 1 for immune-mediated inflammatory disorders, plus preclinical NEU-627 for neuroinflammation). The drug programs are paired with a proprietary machine learning patient selection model and a first-in-class NGS companion diagnostic (developed with QIAGEN) that identifies patients with LRRK2-driven Parkinson's disease.

Product overview

Neuron23 is a clinical-stage biotechnology company developing a portfolio of precision medicines for genetically defined neurological and immunological diseases. The company's pipeline includes three clinical-stage programs: NEU-411 (Phase 2, LRRK2 inhibitor for Parkinson's disease), NEU-723 (Phase 1 completed, LRRK2 inhibitor for PD), and NEU-111 (Phase 1, TYK2 inhibitor for immune-mediated disorders). The pipeline is supported by a precision medicine platform that integrates machine learning-based patient selection algorithms, companion diagnostics developed with QIAGEN for genetic testing, and digital biomarker technology from Roche for disease monitoring. The company is also advancing NEU-627, a brain-penetrant TYK2 inhibitor for multiple sclerosis.

Differentiator

Problem solved

Functional benefit

Products and services

  • NEU-411 A brain-penetrant, potent and selective oral inhibitor of LRRK2 kinase currently being evaluated in the global Phase 2 NEULARK clinical trial for early Parkinson's disease. Targets LRRK2-driven PD affecting up to 30% of people with idiopathic Parkinson's disease, offering a disease-modifying approach versus existing symptomatic-only treatments.
  • NEU-723 A highly potent and selective brain-penetrant LRRK2 inhibitor that completed first-in-human Phase 1 clinical trial in healthy volunteers. Demonstrated strong disease-modifying potential with a higher therapeutic index than other LRRK2 candidates in development.
  • NEU-111 A potent and highly selective oral allosteric inhibitor of TYK2 (tyrosine kinase 2) in Phase 1 clinical trials for immune-mediated inflammatory disorders. Reduces signaling through cytokine receptors including IL-12, IL-23 and interferon-alpha with potential applications in inflammatory bowel diseases, lupus, rheumatoid arthritis, and Type 1 diabetes.
  • NEU-627 A brain-penetrant TYK2 inhibitor in preclinical development for multiple sclerosis and neuroinflammatory diseases, representing Neuron23's expansion into neuroinflammatory conditions.
  • Precision Medicine Platform An integrated platform combining machine learning algorithms, human genetics, and biomarker discovery to identify genetic signatures predictive of therapeutic response. Utilizes companion diagnostics (developed with QIAGEN) and digital biomarkers (with Roche) to enable patient stratification and selection for targeted therapies.

Quantifiable outcome

  • LRRK2 pathway engagement demonstrated with dramatic reductions in pS935-LRRK2 in blood and cerebrospinal fluid
  • +3 more outcomes

Companies that use Neuron23

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Neuron23 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability2 records

Feature5 records

Neuron23 partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major, minor and core.

  • Parkinson's FoundationmajorStrategic or Co-development Partner · 26 May 2026PD Trial Navigator program partnership. Foundation identified over 2,000 genetically eligible potential participants for NEULARK clinical trial by leveraging PD GENEration database of over 30,000 genetically tested Parkinson's patients combined with Neuron23's precision medicine tools.
  • Tisch InstituteminorStrategic or Co-development Partner · 25 March 2025Research collaboration for nonclinical studies on TYK2 inhibitors demonstrating impact in EAE model of multiple sclerosis and neuroinflammation. Studies conducted in collaboration with the Tisch Institute contributed to PNAS publication.
  • Roche Information SolutionscoreTechnology or Integration · 19 November 2024Collaboration to incorporate digital biomarker developed by Roche as primary endpoint in Phase 2 NEULARK clinical trial. Roche provides device hardware, software, site support, and digital biomarker development expertise. Participants use smartphone equipped with proprietary software to measure PD symptoms.
  • Sano GeneticscoreStrategic or Co-development Partner · 19 November 2024Partnership to streamline patient referrals for NEULARK clinical trial. Sano offers saliva test kits that can identify people with LRRK2-driven PD and provides genetic counseling and engagement tools. Identified individuals referred to nearest NEULARK site.
  • QIAGENcoreTechnology or Integration · 14 September 2022Master Collaboration Agreement to develop companion diagnostic for LRRK2 inhibitor for Parkinson's disease. QIAGEN developing clinical trial assay using NGS workflow to detect biomarkers predictive of patient responsiveness. Quest Diagnostics deploying assay at laboratory in San Juan Capistrano, CA under exclusive agreement.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Neuron23 competitors and assessment

Company assessment

Direct peers

  • Denali Therapeutics: Denali Therapeutics is the most directly comparable peer, developing a brain-penetrant LRRK2 inhibitor (BIIB122/DNL151) for Parkinson's disease in partnership with Biogen. Both companies target LRRK2-driven PD using a similar precision medicine framing and represent the leading edge of LRRK2 clinical development globally.
  • Prothena: Prothena is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases including Parkinson's and Alzheimer's, sharing Neuron23's CNS drug development focus and clinical-stage biotech operating model.
  • Annexon: Annexon is a clinical-stage biopharmaceutical company developing complement-mediated therapies for neurodegenerative diseases, sharing Neuron23's focus on targeted therapeutics for neurological conditions and clinical-stage development posture.
  • Voyager Therapeutics: Voyager Therapeutics is a clinical-stage gene therapy company with Parkinson's disease programs (including tau-targeted and GBA1 approaches), mirroring Neuron23's targeted therapeutic strategy for genetically defined CNS disease subpopulations.
  • Sage Therapeutics: Sage Therapeutics developed CNS-targeting therapeutics (Zulresso, Zurzuvae) with a similar focus on neurological and neuropsychiatric indications, mirroring Neuron23's CNS drug development profile; acquired by Biogen in 2024.
  • Prevail Therapeutics: Prevail Therapeutics was a clinical-stage gene therapy company developing AAV-based therapies for neurodegenerative diseases including Parkinson's disease with GBA1 mutations, acquired by Eli Lilly in 2021 for ~$880M. It shares Neuron23's precision medicine approach to genetically defined PD subpopulations.
  • Cerevel Therapeutics: Cerevel Therapeutics is a clinical-stage neuroscience company developing therapies for CNS disorders including Parkinson's disease, sharing Neuron23's CNS therapeutic focus, clinical-stage operating model, and similar investor sponsorship structure (including with Pfizer legacy program assets).

Broad incumbents

  • Intra-Cellular Therapies: Intra-Cellular Therapies develops CNS therapeutics (CAPLYTA for schizophrenia and bipolar depression) with broader neuroscience focus, established regulatory and commercial infrastructure that parallels Neuron23's CNS disease focus at greater scale.
  • Acadia Pharmaceuticals: Acadia Pharmaceuticals is an established biopharmaceutical company commercializing CNS therapies including treatments for Parkinson's disease psychosis (NUPLAZID), representing a commercially validated competitor/incumbent in the PD therapeutic market.

Others

  • Biogen: Biogen is a large biopharmaceutical company with established CNS franchise (TYSABRI, SPINRAZA, ADUHELM) that partners with Denali on the leading LRRK2 inhibitor; represents the type of potential strategic acquirer/partner for Neuron23's NEU-411 program.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Neuron23 social profiles

Digital presence

Neuron23 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neuron23 leadership team

Management profile

Number of profiles

Profiles15 records

Neuron23 funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neuron23 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuron23

What does Neuron23 do?

Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined neurological and immunological diseases. Its pipeline comprises brain-penetrant LRRK2 inhibitors (lead asset NEU-411 in Phase 2 NEULARK for early Parkinson's disease, plus NEU-723) and TYK2 inhibitors (NEU-111 in Phase 1 for immune-mediated inflammatory disorders, plus preclinical NEU-627 for neuroinflammation). The drug programs are paired with a proprietary machine learning patient selection model and a first-in-class NGS companion diagnostic (developed with QIAGEN) that identifies patients with LRRK2-driven Parkinson's disease.

Is Neuron23 a public or private company?

Neuron23 is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neuron23 founded?

Neuron23 was founded in 2018. It employs 11 to 50 people.

Where is Neuron23 based?

Neuron23 is headquartered in South San Francisco, United States, in the North America region.

How does Neuron23 make money?

Two revenue lines are on record. Pharmaceutical/Drug Development and Commercialization is the primary driver. The others are companion Diagnostic Partnerships.

Who are Neuron23's main competitors?

Direct peers on record are Denali Therapeutics, Prothena, Annexon, Voyager Therapeutics, Sage Therapeutics, Prevail Therapeutics and Cerevel Therapeutics. Broad incumbents are Intra-Cellular Therapies and Acadia Pharmaceuticals. Biogen is listed as an others.

Does Neuron23 have an API?

No public API is recorded for Neuron23.

What industry is Neuron23 in?

Neuron23's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAAANAH, Patient Stratification, Risk Prediction & Prognostic Modeling. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Neurology livePhase 2 Trial of LRRK2 Inhibitor NEU-411 Expands Following Michael J. Fox Foundation GrantNeuron23 announced it received a $2.5 million grant from the Michael J. Fox Foundation to expand its phase 2 NEULARK trial of NEU-411 into Israel, activating four sites in Tel Aviv, Jerusalem and Haifa. The double-blind, placebo-controlled study enrolls about 150 early-stage LRRK2-driven Parkinson's patients for 52 weeks, with Roche digital biomarkers as the primary endpoint. The Parkinson's Foundation's PD Trial Navigator program supports recruitment.Pulse 2.0Neuron23 Receives $2.5 Million Grant From The Michael J. Fox Foundation To Expand Phase 2 Parkinson’s TrialNeuron23, a clinical-stage biotechnology company developing precision medicines for Parkinson's disease, received a $2.5 million grant from The Michael J. Fox Foundation to support expansion of its ongoing Phase 2 NEULARK clinical trial of NEU-411 into Israel. The funding will enable activation of four clinical trial sites across Israel and patient screening for individuals with early Parkinson's disease who may have LRRK2-driven disease. The global Phase 2 trial is designed to enroll approximately 150 participants who will receive NEU-411 or placebo daily for 52 weeks, using digital biomarker technology developed by Roche to monitor motor and non-motor symptoms.BioSpaceNeuron23 to Accelerate Expansion of NEULARK Phase 2 Trial with Support from The Michael J. Fox FoundationNeuron23 Inc. announced it received a $2.5 million grant from The Michael J. Fox Foundation to expand its Phase 2 NEULARK trial of LRRK2 inhibitor NEU-411 into Israel, activating four sites in Tel Aviv, Jerusalem and Haifa. The global trial enrolls about 150 participants over 52 weeks, using Roche digital biomarkers.Business Wire BlogNeuron23 to Accelerate Expansion of NEULARK Phase 2 Trial with Support from The Michael J. Fox FoundationNeuron23 Inc. has received a $2.5 million grant from The Michael J. Fox Foundation for Parkinson's Research to support expansion of its ongoing Phase 2 NEULARK clinical trial into Israel. The funding will enable activation of four clinical trial sites across Tel Aviv, Jerusalem, and Haifa for screening patients with early Parkinson's disease who may have LRRK2-driven disease. The trial is evaluating NEU-411, a LRRK2 inhibitor, in approximately 150 participants globally over a 52-week treatment period.FinancialContent Business PageNeuron23 to Accelerate Expansion of NEULARK Phase 2 Trial with Support from The Michael J. Fox FoundationNeuron23 Inc. announced receiving a $2.5 million grant from The Michael J. Fox Foundation for Parkinson's Research to support expansion of its Phase 2 NEULARK clinical trial of NEU-411 into Israel, with activation of four clinical trial sites across Israel and patient screening efforts for people with early LRRK2-driven Parkinson's disease. The global trial is evaluating a precision medicine approach targeting the LRRK2 gene, which is among the most common genetic causes of Parkinson's disease, affecting approximately 2% of patients and potentially up to 30% of those with idiopathic PD. The funding enables Neuron23 to leverage Israel's exceptional Parkinson’s research and clinical community while incorporating digital biomarker technology developed by Roche Information Solutions to monitor motor and non-motor symptoms.Neuron23Neuron23Neuron23 received a $2.5 million grant from The Michael J. Fox Foundation to expand its Phase 2 NEULARK trial of NEU-411 into Israel, activating four clinical sites. The trial targets LRRK2-driven Parkinson's disease and has screened the first Israeli patient. The global trial enrolls about 150 participants over 52 weeks.pharmaphorumParkinson's charity partners Biognosys on biomarker projectThe Michael J. Fox Foundation and Biognosys are developing quantitative LRRK2 biomarker assays to guide Parkinson's drug development. The partnership aims to support LRRK2-directed therapies, with several clinical trials ongoing, including Denali's DNL151 and Neuron23's NEU-411.TipranksNeuron23 Highlights Precision-Medicine Strategy in Parkinson’s DiseaseNeuron23 shared a LinkedIn post outlining its precision-medicine approach to Parkinson's disease, highlighting the biological heterogeneity of the condition and the limitations of traditional treatment paradigms. The company is focusing on identifying genetic signatures linked to overactivity in the LRRK2 pathway to better select patients who may respond to targeted interventions. The post positions this genetics-based strategy as a potential differentiator for trial design and competitive positioning within the neurology space.SilverwoodpartnersHealthcare Private Placement and M&A Transactions Review Week Ending June 29, 2025This report summarizes multiple private placement and M&A transactions in the healthcare sector for the week ending June 29, 2025. Notable deals include Illumina's $425 million acquisition of SomaLogic and various venture funding rounds for companies such as Abridge, Neuron23, and Arthrosi Therapeutics. The data covers activities across biotechnology, digital health, and medical devices.AlleyWatchThe Weekly Notable Startup Funding Report: 6A weekly report on notable startup funding rounds for the week ending June 28, 2025, covers 24 deals totaling $1.56B. Highlights include Harvey's $300M round and Abridge's $300M round, with other companies like Flexiv, Neuron23, and Digital Asset also receiving funding.